MedTrace Logo

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

NCT00038675 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2022-01-04

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), can improve the disease condition in patients with hypereosinophilic syndrome, polycythemia vera, atypical CML or CMML with PDGF-R fusion genes, or mastocytosis.

Conditions

  • Chronic Myelomonocytic Leukemia
  • Chronic Myeloid Leukemia
  • Polycythemia Vera
  • Hypereosinophilic Syndrome
  • Mastocytosis

Interventions

DRUG

Imatinib Mesylate (Gleevec)

Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily

Sponsors & Collaborators

Principal Investigators

  • Jorge Cortes, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038675 on ClinicalTrials.gov